Hemcheck Sweden AB has signed an exclusive distribution agreement with Abdulla Fouad for Medical Supplies and Services Company (“AFMS”), a leading distributor of laboratory and medical equipment in Saudi Arabia. The agreement will be in force from April and valid until the end of September 2023, concerning the Saudi Arabian market. AFMS has committed to an initial purchase order of readers and one-time tests for a value of 8,000 EUR.

– AFMS is a large and well established distributor in Saudi Arabia representing well known global companies and is working in segments highly relevant to Hemcheck. We believe they are a very good partner for us in Saudi Arabia and we look forward to starting the collaboration, says Joen Averstad, CEO of Hemcheck.

– We are very happy to start this collaboration with Hemcheck. They have a very interesting and unique solution. We look forward to initiating the local registration process and start the efforts to approach customers, says Faisal Abdulla Fouad, Chairman of Abdulla Fouad Group.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About Abdulla Fouad for Medical Supplies and Services Company

Abdulla Fouad for Medical Supplies and Services Company is a part of Abdulla Fouad Group, and has served the healthcare sector in Saudi Arabia for over 35 years. It covers a wide range of healthcare requirements, including diagnostics, rehabilitation, radiopharmaceuticals, sanitation, medical consumables and supplies. It is a partner in the local market to global companies such as Becton Dickinson, Thermo Scientific, Werfen and Beckman Coulter.

Read more at https://www.afmssc.com/

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.

Important information

This information is such information that Hemcheck is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on April 15, 2021 at 10.10